COMMUNIQUÉS West-GlobeNewswire

Oculis to Participate in Upcoming Investor Conferences
05/03/2026
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
Oculis Publishes 2025 Consolidated Financial Statements
05/03/2026
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A, which have now [...]
Oculis to Participate in Upcoming Investor Conferences
05/03/2026
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
05/03/2026
Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Paris, March 5 , 202 6 . The Board of Directors of Sanofi has decided to propose, at the next Annual General Meeting [...]
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
05/03/2026
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated [...]
Communiqué de presse : Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante
05/03/2026
Le Conseil d’administration de Sanofi propose la nomination de C hristel Heydemann en qualité d’administrat rice indépendant e Paris , le 5 mars 202 6 . Le Conseil d’administration de Sanofi a décidé de proposer, dans [...]
Swarm Oncology appoints Bernhard Ehmer as Chairman
05/03/2026
Company announces manufacturing readiness and financing extension ahead of first-in-human clinical study London, United Kingdom, March 5, 2026, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm” or “the Company”), a [...]
NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
05/03/2026
Ghent, Belgium, March 05, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION - INSIDE INFORMATION 5 March 2026, 7:00 am CET Ghent, Belgium, 5 March 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " [...]
BioVersys to Report Its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call
05/03/2026
BASEL, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious [...]
Phonak Infinio Ultra Sphere and Virto R Infinio win 2026 iF DESIGN AWARD
05/03/2026
Both Phonak hearing aids recognized for seamlessly integrating breakthrough technology with intuitive usability and refined industrial design STÄFA, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Phonak , a global [...]
SugarHarmony Consumer Concerns Under Investigation: Critiquing The Sugar Harmony Claims
05/03/2026
An informational 2026 consumer evaluation examining common SugarHarmony search queries, ingredient transparency concerns, marketing claim context, refund and fulfillment policy requirements, and what verification steps [...]
Purisaki Berberine Patches Claims Evaluated: 2026 Consumer Report on Transdermal Berberine Delivery, Patch Absorption Science, and What Buyers Should Verify
05/03/2026
An informational 2026 consumer report examining Purisaki Berberine Patches' transdermal delivery claims, ingredient research context, pricing structure, and what to confirm before purchasing Wayne, NJ, March 04, 2026 ( [...]
Medline Inc. announces pricing of secondary offering of class A common stock
05/03/2026
NORTHFIELD, Ill., March 04, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of a previously announced secondary offering of 75,000,000 shares of Medline Inc.’s Class A common [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
04/03/2026
ZUG, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' [...]
DBV Technologies to Participate in Upcoming March Investor Conferences
04/03/2026
Châtillon, France, March 4, 2026 DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical [...]
DBV Technologies annonce sa participation à plusieurs conférences investisseurs en mars
04/03/2026
Châtillon, France, le 4 mars (22 :30 CET) 2026 DBV Technologies annonce sa participation à plusieurs conférences investisseurs en mars DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT [...]
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
04/03/2026
SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and [...]
Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
04/03/2026
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee. Effective March 1, 2026, in [...]
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
04/03/2026
–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 [...]

Pages